The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback